Allergan shareholders reject proposal to split roles of chairman and CEO

pharmafile | May 2, 2019 | News story | Research and Development Allergan, Appaloosa, CEO, board of directors, hedge fund, pharma 

Allergan shareholders have rejected a proposal to immediately separate the roles of CEO and chairman, both of which are currently held by Brent Saunders.

The proposal, put forward by hedge fund Appaloosa, was rejected by 61.3% of shareholders.

“The Allergan board appreciates the support of our shareholders reflected in the voting results” Allergan said. The motion comes after the company agreed to split the roles in the next leadership transition.

The firm however argued that splitting the roles immediately, as requested by Appaloosa, “could impede the board’s effectiveness by creating a crisis of confidence in Saunders at a time when leadership stability and effectiveness is critical.”

The push from Appaloosa comes after the investigational therapy rapastinel failed to improve outcomes in three late-stage studies of major depressive disorder.

The hedge fund has also pushed for a merger unless management are held to account. Allergan posted a fourth-quarter loss of $4.3 billion in the final three months of 2018.

Louis Goss

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content